Clinical Trials · NCT06025409
Evaluate the Efficacy and Safety of DWJ108J
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Enrollment
- 79
- Start date
- Aug 2023
- Locations
- 1 site, South Korea
- Primary endpoint
- Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.